| Q38246665 | 5-Hydroxytryptamine3 receptor antagonists and cardiac side effects. |
| Q48717197 | A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer |
| Q42528919 | A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy |
| Q44682779 | A phase I/II study of the 5-HT3 antagonist GR38032F in the anti-emetic prophylaxis of patients receiving high-dose cisplatin chemotherapy |
| Q54435297 | A phase II antiemetic combination (COMD) for cisplatin-induced nausea and vomiting. |
| Q55668999 | Acupuncture prophylaxis of cancer chemotherapy-induced sickness. |
| Q39739860 | Adrenal corticosteroids as antiemetics during cancer chemotherapy |
| Q36911183 | Advances in the management of cytotoxic drug-induced nausea and vomiting |
| Q68160672 | Amelioration of cytotoxic-induced emesis with high-dose metoclopramide, dexamethasone and lorazepam |
| Q41880882 | Antiemetic efficacy of high-dose dexamethasone: randomized, double-blind, crossover study with a combination of dexamethasone, metoclopramide and diphenhydramine |
| Q48940677 | Antiemetic therapy for chemotherapy-induced vomiting: metoclopramide, benztropine, dexamethasone, and lorazepam regimen compared with chlorpromazine alone |
| Q40673130 | Antiemetics in cancer chemotherapy: historical perspective and current state of the art. |
| Q37039597 | Antiemetics: an update and the MASCC guidelines applied in clinical practice |
| Q43582725 | Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis |
| Q37783929 | Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy. |
| Q68242806 | Continuous infusion of high-dose metoclopramide: comparison of pharmacokinetically adjusted and standard doses for the control of cisplatin-induced acute emesis |
| Q42693199 | Contribution to the treatment of nausea and emesis induced by chemotherapy in children and adolescents with osteosarcoma |
| Q37199898 | Controlling Emesis in Patients Receiving Cancer Chemotherapy |
| Q33284409 | Controlling cancer chemotherapy-induced emesis |
| Q40757801 | Delayed emesis: a dilemma in antiemetic control |
| Q46605523 | Diphenhydramine for nausea and vomiting related to cancer chemotherapy with cisplatin |
| Q74082735 | Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation |
| Q44658479 | Effects of ondansetron on chemotherapy-induced acute and delayed emesis--a pilot study |
| Q42136434 | Efficacy of Ondansetron (Gr 38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and Vomiting |
| Q42372681 | Enhancement of the antiemetic action of ondansetron by transcutaneous electrical stimulation of the P6 antiemetic point, in patients having highly emetic cytotoxic drugs |
| Q51699074 | Five-drug antiemetic combination for cisplatin chemotherapy |
| Q69299648 | GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting |
| Q52253770 | Glucocorticoids attenuate taste aversions produced by toxins in rats. |
| Q36711574 | Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic |
| Q38563457 | Granisetron: the second serotonin-receptor antagonist |
| Q33711620 | Guidelines for anti-emetic therapy: acute emesis |
| Q68211602 | High-dose metoclopramide by infusion: a double-blind study of plasma concentration-effect relationships in patients receiving cancer chemotherapy |
| Q36080616 | Methylprednisolone enhances the efficacy of ondansetron in acute and delayed cisplatin-induced emesis over at least three cycles. Ondansetron Study Group |
| Q35707858 | Modulation of cis-diamminedichloroplatinum(II) resistance: a review |
| Q35606502 | Myths and realities of antiemetic treatment |
| Q77904056 | Nitrogen-containing heteroalicycles with serotonin receptor binding affinity: development of gastroprokinetic and antiemetic agents |
| Q41128422 | Normal tissue reactions in mice after combined treatment with metoclopramide and ionizing radiation |
| Q68435561 | Ondansetron (GR38032) in the prophylaxis of acute and delayed cisplatin-induced emesis |
| Q41769603 | Ondansetron (GR38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy |
| Q40490584 | Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting |
| Q36660314 | Ondansetron. Therapeutic use as an antiemetic |
| Q33560391 | Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy |
| Q67905486 | Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient |
| Q72098171 | Participation of Serotonin on Early and Delayed Emesis Induced by Initial and Subsequent Cycles of Cisplatinum‐Based Chemotherapy: Effects of Antiemetics |
| Q95811358 | Pharmacological Agents Affecting Emesis : A Review (Part II) |
| Q33330545 | Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812). |
| Q37199907 | Present Role of Corticosteroids as Antiemetics |
| Q40757798 | Progress in controlling emesis with cancer chemotherapy |
| Q51663279 | Propofol and chemotherapy emesis. |
| Q36134463 | Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin |
| Q51737323 | Randomized crossover comparison of high-dose intravenous metoclopramide versus a five-drug antiemetic regimen. |
| Q40387103 | Reducing chemotherapy-induced nausea and vomiting. Current perspectives and future possibilities |
| Q42601066 | The anti-emetic efficacy and tolerability of tropisetron in patients conditioned with high-dose chemotherapy (with and without total body irradiation) prior to bone marrow transplantation |
| Q39758993 | The management of chemotherapy-induced nausea and vomiting |
| Q42660491 | The pharmacokinetics of single high doses of dexamethasone in cancer patients |
| Q36467992 | The role of metoclopramide in acute and delayed chemotherapy induced emesis: a randomised double blind trial |
| Q60170570 | Therapeutic efficacy of various dosages and modalities of administration |
| Q39637634 | Therapeutic progress--review XXVIII. Are we making progress in the management of cytotoxic drug-induced nausea and vomiting? |
| Q44637209 | Transient reduction in serum cortisol levels after dexamethasone antiemetic therapy in cancer patients undergoing chemotherapy |
| Q40655344 | Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists |
| Q40872768 | Tropisetron (ICS 205-930): a selective 5-hydroxytryptamine antagonist |
| Q40385730 | Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic |
| Q35332522 | Tropisetron. A review of the clinical experience |
| Q51758720 | Two antiemetic regimens do not impair chemical xenogenization induced in vivo by 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide. |
| Q72522017 | [Antiemetic treatment and chemotherapy: general review] |
| Q83944098 | [Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research] |